| Species |
Human |
| Protein Construction |
HVEM/TNFRSF14 (Leu39-Val202)
Accession # Q92956-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HVEM/TNFRSF14, His, Human at 2μg/ml (100 μl/Well) on the plate can bind Human CD160, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 32-48 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Herpesvirus entry mediator (HVEM), also known as tumor necrosis factor receptor superfamily member 14 (TNFRSF14), is a human cell surface receptor of the TNF-receptor superfamily. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling. |
| Synonyms |
CD270; CD40-like protein; HVEM; LIGHTR; ATAR; TNFRSF14; TR2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
